LURASIDONE HYDROCHLORIDE

Post-LOE

lurasidone hydrochloride

Jubilant Therapeutics

ANDAORALTABLET

Approved

Aug 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LURASIDONE HYDROCHLORIDE (lurasidone hydrochloride) by Jubilant Therapeutics is unclear. Approved for adolescent patients (13 to 17 years) with schizophrenia [see clinical studies ( )], schizophrenia, depression and 1 more indications. First approved in 2024.

Drug data last refreshed 18h ago

Mechanism of Action

unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D 2 and serotonin Type 2 (5HT 2A ) receptor antagonism.

Indications (2)

schizophrenia depression

Worked on LURASIDONE HYDROCHLORIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.